Objective: The purpose of this study was to determine the effect of adjuvant premeal pramlintide with postmeal insulin on postprandial hyperglycemia in children with type 1 diabetes mellitus (T1DM).
Methods: Eight adolescents with T1DM on intensive insulin therapy participated in an open-label, non-randomized, crossover study, comparing postprandial glucose excursions in study A (prescribed insulin regimen and given premeal) vs. study B (pramlintide + insulin). Prandial insulin dose for study B was decreased by 20% and given postmeal, while pramlintide was given just before the meal. Blood glucose (BG), glucagon, and pramlintide concentrations were measured basally and at timed intervals during a 300-min study period.
Results: Postprandial incremental BG for the duration of the study was reduced in study B vs. study A with AUC((-60 to 300 min)) (area under the curve) at 6600 +/- 2371 vs. 20 230 +/- 3126 mg/dL/min (367 +/- 132 vs. 1124 +/- 174 mmol/L/min) (p < 0.001). Glucagon concentration was suppressed for approximately 120 min following administration of 30 microg of pramlintide and postmeal insulin (p < 0.003). No severe hypoglycemic episodes were experienced in this study.
Conclusions: Postprandial hyperglycemia is considerably reduced in adolescents with T1DM when treated with fixed-dose premeal pramlintide, and precisely calculated postmeal insulin, without significant side effects.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1399-5448.2008.00490.x | DOI Listing |
Diabetes Metab
December 2024
Institut de recherches cliniques de Montréal, Canada; Département de Nutrition, Faculté de Médecine, Université de Montréal, Canada; Endocrinology Division and Montreal Diabetes Research Center, Canada. Electronic address:
Objective: We investigated strategies to mitigate hypoglycemic risk during and after different aerobic exercises in people with type 1 diabetes (pwT1D) using continuous subcutaneous insulin infusion.
Research Design And Methods: Thirty-seven pwT1D (21 adults, 16 adolescents; HbA1c = 7.5 ± 1.
Biomedicines
November 2024
Department of Clinical Medicine and Surgery, Federico II University, 80131 Naples, Italy.
Background: Endothelial dysfunction is recognized as an early modification involved in the pathogenesis of vascular diseases. Evidence suggests that the Mediterranean Diet (MD) is associated with endothelial function improvement and, in turn, plays an important role in atherosclerosis development and progression.
Objectives: To evaluate both acute and sustained effects of the MD on endothelial function in patients with high cardiometabolic risk.
Diabetes Metab Syndr Obes
November 2024
Clinical Science Department, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
Acta Med Indones
July 2024
Division Endocrinology, Department of Internal Medicine, Faculty of Medicine Universitas Diponegoro - Dr. Kariadi General Hospital, Semarang, Indonesia.
Background: DLBS3233, recognized as an agent enhancing insulin sensitivity, has exhibited promise as a therapeutic option for addressing type 2 diabetes mellitus (T2DM). This study aimed to evaluate the effectiveness and safety of DLBS3233, a natural compound, in individuals newly diagnosed with T2DM.
Methods: A 12-week double-blind, randomized, placebo-controlled clinical trial was conducted with 104 eligible participants.
Nutrients
October 2024
Department of Internal Medicine, Amsterdam University Medical Center, VU University Medical Center, 1081 HV Amsterdam, The Netherlands.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!